VI 型分泌系统 （T6SS） 在弧菌属中分布广泛，但其在产毒菌株和非产毒菌株共存中的作用，目前仍不清 楚。 2025 年 7 月 9 日，南方科技大学 傅暘 研究员团队 在 Cell 子刊 Cell Host & Microbe 上发表了题为： A Vibrio-specific T6SS effector reshapes microbial competition by disrupting Vibrio bioenergetics 的 研究论文，该论文被选为当期封面论文。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 非产毒型霍乱弧菌可通过体内/体外的 Ⅵ 型分泌系统 （T6SS） 在竞争中占据优势地位，战胜产毒 型对手； TseV 通过膜去极化和 ATP 耗竭使弧菌生物能量学崩溃； TseV 主要武装非产毒弧菌，维持遗传多样性； TseV 的杀弧菌特异性使精准抗菌药物得以保留微生物群。 总的来说，这些研究结果表明，TseV 代表了一种很有前景的精准抗菌策略模型，能将对共生微生物群的附 带损害降至最低。 论文链接 ： https://www.cell.com/cell-host-microbe/abstra ...

Core Viewpoint - Innovent Biologics has presented promising clinical data for IBI354, a HER2 monoclonal antibody-camptothecin derivative conjugate, at the 2025 ASCO Annual Meeting, highlighting its potential in treating advanced solid tumors, particularly in ovarian and breast cancer [1][2]. Group 1: Clinical Data and Efficacy - IBI354 has shown promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors, indicating its potential as a new generation of ADC therapies characterized by high potency and low toxicity [2][5]. - The Phase 1/2 clinical study enrolled 368 participants with advanced solid tumors, with a median follow-up duration of 11.5 months and a median treatment duration of 27.0 weeks [3]. - In the ovarian cancer cohort, IBI354 achieved an objective response rate (ORR) of 55.0% and a disease control rate (DCR) of 90.0% at a dose of 12mg/kg Q3W, with a median progression-free survival (PFS) of 7.1 months [6][7]. Group 2: Safety Profile - IBI354 demonstrated an excellent safety profile, with a low incidence of treatment-related adverse events (TRAEs) and no dose-limiting toxicities (DLTs) observed at escalated doses [4][7]. - The most common TRAEs included anemia, nausea, and decreased white blood cell count, with only 1.9% of patients experiencing interstitial lung disease [7]. Group 3: Future Development and Strategic Positioning - The Phase 3 study of IBI354 in platinum-resistant ovarian cancer has been initiated, indicating the company's commitment to further validating the long-term benefits of this treatment [8]. - Innovent is advancing its strategic layout in the ADC field, with plans for additional clinical studies and investments in next-generation ADC molecules to address unmet clinical needs [8][10].